JP2004229611A - Anti-uv food composition - Google Patents

Anti-uv food composition Download PDF

Info

Publication number
JP2004229611A
JP2004229611A JP2003025049A JP2003025049A JP2004229611A JP 2004229611 A JP2004229611 A JP 2004229611A JP 2003025049 A JP2003025049 A JP 2003025049A JP 2003025049 A JP2003025049 A JP 2003025049A JP 2004229611 A JP2004229611 A JP 2004229611A
Authority
JP
Japan
Prior art keywords
skin
elastin
ceramide
carotene
food composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003025049A
Other languages
Japanese (ja)
Other versions
JP4114186B2 (en
Inventor
Kazuya Ikuta
一哉 幾田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J Oil Mills Inc
Original Assignee
J Oil Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Oil Mills Inc filed Critical J Oil Mills Inc
Priority to JP2003025049A priority Critical patent/JP4114186B2/en
Publication of JP2004229611A publication Critical patent/JP2004229611A/en
Application granted granted Critical
Publication of JP4114186B2 publication Critical patent/JP4114186B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food composition having excellent effect to prevent or ameliorate the inflammation of the skin induced by ultraviolet rays and the degradation of the skin caused by the inflammation. <P>SOLUTION: The food composition is composed of a carotenoid incorporated with elastin or its decomposition product and/or ceramide or its glycoside. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は、紫外線により誘発される皮膚の炎症とそれに伴う皮膚の劣化を、予防又は軽減することを目的とした食品組成物に関するものである。
【0002】
【従来の技術】
近年、オゾンホールの拡大に伴い、紫外線による健康被害の増加が、世界的な問題となっている。気象庁の報告によれば、観測を開始した1979年には、ほとんどみられなかった南極域上空のオゾンホールは、その後、急激に拡大の一途をたどり、2000年には約3000万平方キロメートルにまで達している(非特許文献1を参照)。これは南極大陸の面積のおよそ2倍に匹敵する。北半球では、今のところはっきりとしたオゾンホールは観測されていないが、南半球と同様に上空のオゾン量が減少しており、その結果、地表に届く有害な紫外線量の増加も確認されている。
【0003】
南極大陸に近いオーストラリアでは、紫外線による皮膚がんの発症率が、他の国に比べて、圧倒的に高いことが報告されている(非特許文献2を参照)。また北半球のフィンランドでも、皮膚がんの発症率が、年々増加傾向にあることが報告されている(非特許文献3を参照)。我が国でも、特に高緯度地域において上空のオゾン量の長期的な減少傾向が観測されており(非特許文献1を参照)、今後、皮膚がんなど、紫外線による疾病が増加することが懸念されている。
【0004】
皮膚が強い紫外線に曝されると、紅斑(皮膚発赤)や浮腫などのダメージを受け、その結果、肥厚や弾性喪失、シワ発生、色素沈着異常など皮膚の劣化が引き起こされる。さらに、強い紫外線への繰り返しの被爆は、皮膚がんのリスクを増大させる。一方で、年間を通じて皮膚が曝されている弱い紫外線、いわゆる生活紫外線も、皮膚の劣化を引き起こす原因になることが報告されている(非特許文献4を参照)。こうした紫外線による健康被害を防ぐため、これまで皮膚へ塗布する日焼け止めクリームや化粧品などの外用剤が、紫外線から皮膚を保護する主な手段として用いられてきた。しかしながら、外出の度に、皮膚外用剤を身体の露出している部分すべてに、完全に塗布することは困難であるばかりでなく、手間と時間もかかってしまうことから、より手軽で有効な紫外線対策の手段が望まれている。
【0005】
この課題を解決すべく、経口摂取によって皮膚を紫外線から保護する効果のある薬理成分に関して、数多くの研究がなされている。ヒト皮膚のビタミンC、ビタミンE、カロチノイドの濃度は、紫外線に曝されることによって低下することが報告されている。これらの知見にもとづき、ヒトがビタミンC、ビタミンE、カロチノイドを経口摂取した場合に、紫外線による皮膚のダメージを軽減できるかについても検討がなされている。カロチノイドを例にとると、β−カロチンやリコピンの経口摂取により、紫外線により誘発される皮膚の炎症(紅斑)が抑えられたとする報告がなされている(例えば、非特許文献5および6を参照)。しかしながら、これらカロチノイド単独の摂取は、いずれも効果が認められるまでに10週間程度と長い時間を要するばかりでなく、化粧品などの皮膚外用剤に比べると、紅斑抑制の効果も十分であるとは言い難いという欠点があった。
【0006】
また、紫外線は、皮膚のビタミンC、ビタミンE、カロチノイドの濃度を低下させるだけでなく、皮膚の弾力組織の量も減少させることが報告されている(非特許文献7を参照)。皮膚の弾力組織の主たる成分は、真皮に存在するエラスチンと呼ばれるタンパク質であり、デスモシン、イソデスモシンといった特有のアミノ酸を含んでいることから、栄養学的にも注目されつつある。しかしながら、エラスチンの経口摂取による皮膚への効果に関しては、熱傷皮膚の回復を早めることが動物試験により報告されているのみ(非特許文献8を参照)で、紫外線に対する皮膚の保護効果については、ヒト試験のみならず動物試験においても、何ら報告されていない。
【0007】
一方、皮膚の最も外側にある表皮は、紫外線に直接曝される部分であり、この表皮の角質層の細胞間脂質のおよそ半分を占めるセラミドは、紫外線に対して何らかの保護作用を持つことが推測される。実際、セラミドにメラニン生成抑制作用があることが報告されている(非特許文献9を参照)が、これはメラノーマ細胞を用いたin vitroでの結果であり、ヒトや動物がセラミドを経口摂取した場合の効果については報告されていない。また、経口摂取する例としては、セラミドを有効成分として含有する健康食品等が提案されているが、これらは主として保湿や美肌を目的としたものである(特許文献1、非特許文献10を参照)。
【0008】
【特許文献1】
特開平11−113530号公報
【非特許文献1】
気象庁気候変動監視レポート2001
【非特許文献2】
Arch. Darmatol., Vol.135, No.7, 843−844 (1999)
【非特許文献3】
Arch. Darmatol., Vol.135, No.7, 781−786 (1999)
【非特許文献4】
J. Invest. Dermatol., Vol.105, No.6, 739−743 (1995)
【非特許文献5】
Proc. Soc. Exp. Biol. Med., Vol.233, 170−174 (2000)
【非特許文献6】
J. Nutr., Vol.131, 1449−1451 (2002)
【非特許文献7】
J. Invest. Dermatol., Vol.105, 739−743 (1995)
【非特許文献8】
総合健康開発研究所報, No.9, 1−7 (2001)
【非特許文献9】
FOOD Style 21, Vol.5, No.8, 24−33 (2001)
【非特許文献10】
FRAGRANCE JOURNAL, 1995−1, 81−89 (1995 )
【0009】
【発明が解決しようとする課題】
このように、経口摂取によって、紫外線による皮膚の炎症を効果的に抑制する食品組成物については、未だに実用化されていないのが現状である。こうした現状に鑑み、本発明は、紫外線により誘発される皮膚の炎症とそれに伴う皮膚の劣化を予防又は軽減するに際して、カロチノイドを単独で摂取した場合よりも効果的な食品組成物を提供せんとするものである。
【0010】
【課題を解決するための手段】
本発明者は、この課題を達成するために鋭意研究を重ねた結果、カロチノイドにエラスチンもしくはその分解物及び/又はセラミドもしくはその配糖体を加えてなる食品組成物を摂取することによって、カロチノイドを単独で摂取した場合よりも、紫外線に誘発される皮膚の紅斑を効果的に抑制し得ることを見出し、本発明を完成させるに至った。
【0011】
すなわち本発明は、紫外線により誘発される皮膚の炎症とそれに伴う皮膚の劣化を予防又は軽減することを目的とした食品組成物に関するものである。
【0012】
【発明の実施の形態】
以下に本発明について説明する。本発明に使用するカロチノイドは、その起源を何ら問うものではなく、β−カロチンであればニンジンやトマトなどの野菜又はデュナリエラなどの藻類から抽出したものがよく、リコピンを使用する場合にはトマトから抽出したものが望ましい。また、他のカロチノイド、すなわちα−カロチンやルテイン、ゼアキサンチン、β−クリプトキサンチンなどを含んでいても何ら問題はなく、これらを混合したミックスカロチノイドを使用することもできる。これらのカロチノイド抽出物は、通常、油脂又は溶剤により抽出される粘調な液体であり、これをそのまま用いることができるほか、賦形剤を加えて粉末化したものを用いてもよい。
【0013】
本発明に使用するエラスチンの起源についても何ら制限はなく、哺乳動物や魚などの皮や結合組織から抽出したものが好ましい。また、抽出したままのエラスチンでも、化学的又は酵素的に処理したエラスチン分解物でもよく、さらには、これらの混合物を使用することもできる。これらの一例としては、タラの皮を細断・ホモジネートし、熱水で抽出した後、酵素処理によって部分的に加水分解し、粉末化することによって製造されるエラスチンがある。
【0014】
本発明に使用するセラミドは、スフィンゴシンに脂肪酸がアミド結合したものの総称として定義され、その起源によって構成分子種に若干の相違がみられるが、ここでは問題とならない。牛などの組織から抽出した動物性のセラミドや、酵母などから抽出した微生物由来のセラミドを使用してもよいが、より好ましくは、配糖体として存在する植物性のセラミド、すなわち一般に入手が可能な米糠、小麦、こんにゃく芋などから抽出したセラミド配糖体を使用するのが望ましい。これらの一例としては、こんにゃく芋を粉砕し、アルコールで抽出した後、粉末化することよって製造されるセラミドがある。
【0015】
これらの原料から製造した本発明の食品組成物は、カロチノイドにエラスチンもしくはその分解物及び/又はセラミドもしくはその配糖体を加えてなることを特徴とし、総カロチノイド又はβ−カロチン又はリコピン1重量部に対して、エラスチン又はその分解物が0.1〜100重量部、セラミド又はその配糖体が0.001〜1重量部であり、好ましくは、総カロチノイド又はβ−カロチン又はリコピン1重量部に対して、エラスチン又はその分解物が1〜10重量部、セラミド又はその配糖体が0.01〜0.1重量部である。本発明の食品組成物を摂取するに際しては、一日の目安量としてカロチノイド換算で1〜100mg、好ましくは、β−カロチンとして20〜50mg、あるいはリコピンとして10〜30mg摂取できるように配合された食品を摂取することによって、カロチノイドを単独で摂取した場合よりも、より短期間で効果的に、紫外線による皮膚の炎症とそれに伴う劣化を予防又は軽減することができる。
【0016】
本発明による食品組成物は、単独で用いることができるほか、皮膚の健康維持に良いとされる他の栄養素、例えば、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ナイアシン、ビオチン、パントテン酸、ビタミンC、ビタミンEなどのビタミン類、亜鉛、セレン、硫黄などのミネラル類、さらにはアミノ酸、グルタチオン、コラーゲン又はその分解物、コンドロイチン、ヒアルロン酸、スクワレン、イソフラボン配糖体又はそのアグリコンなどと組み合わせて用いることが可能である。また、かかる食品組成物の実施形態についても何ら制限するものではなく、他の食品素材と適宜組み合わせることによって、カプセル剤や錠剤などの固形製剤のほか、一般の固形状、半固形状、液状、粉末状食品あるいは飲料などに使用することができる。
【0017】
【実施例】
以下に実施例を示すが、本発明はこれらによって限定されるものではない。
実施例1
オリーブオイルに増粘剤としてミツロウを加えたもの(コントロール、溶液A)をベースとして、これにデュナリエラ由来β−カロチン含有植物油懸濁液(β−カロチン30%含有、協和発酵工業製)のみを配合したもの(溶液B)、タラの皮由来のエラスチン(エラスチン95%含有、アズウェル製)のみを配合したもの(溶液C)、こんにゃく由来のセラミド(セラミド配糖体3%含有、ユニチカ製)のみを配合したもの(溶液D)、β−カロチン含有植物油懸濁液とタラ皮エラスチンを配合したもの(溶液E)、β−カロチン含有植物油懸濁液とこんにゃくセラミドを配合したもの(溶液F)、タラ皮エラスチンとこんにゃくセラミドを配合したもの(溶液G)、β−カロチン含有植物油懸濁液とタラ皮エラスチン及びこんにゃくセラミドを配合したもの(溶液H)の8種類の溶液を調製し、これらを内容液としたゼラチンソフトカプセル(AからH)を作成した。カプセル内容液の配合を表1に、カプセル1粒(内容液500mg)当たりの成分含有量を表2に示す。
【0018】
【表1】

Figure 2004229611
【0019】
【表2】
Figure 2004229611
【0020】
24人のボランティア(男性17人、女性7人、平均年齢32歳)を3人づつ8群に分け、前記の方法によって調製したAからHまでの8種類のカプセルを各群に割り当て、毎日2粒を1日2回に分けて8週間にわたり摂取させた。摂取開始前、摂取開始後4週間および8週間経過の時点で、紫外線照射による皮膚の炎症の程度を評価した。評価方法として、上腕内側部に、1箇所だけ2センチ四方に穴を空けた紫外線防護フィルムを巻き付け、まず紫外線照射前のフィルム開口部の皮膚の色(L0、a0、b0;Lは明度、a及びbは色度を表す)を色差計(ミノルタ Color Reader CR−10)によって測定した。次いで、フィルム開口部に日焼け用紫外線ランプ(フィリップス CLEO 20W×6)を一定の距離から30分間照射し、照射後の皮膚の色(L、a、b)を再び測定し、照射前の皮膚の色との差(ΔL、Δa、Δb)を算出した。なお、4週間毎の3回の測定では、フィルム開口部をずらすことによって、同じ部分の皮膚で測定しないようにした。摂取開始後4週間の時点における紫外線照射による皮膚のΔaの測定値(各群での平均値)を図1に、摂取開始後8週間の時点における紫外線照射による皮膚のΔaの測定値(各群での平均値)を図2に示す。Δa値は赤−緑方向の色度の変化を表し、Δa値が大きいほど皮膚が赤色に変化、すなわち紅斑(紫外線による炎症)が生じていることを示している。
【0021】
図1に示すように、摂取開始後4週間の時点では、カプセルH(β−カロチン+エラスチン+セラミド)摂取群が、カプセルA(コントロール)摂取群に比べてΔa値が有意に低く、紫外線照射による皮膚の発赤、すなわち炎症が有意に抑制されていた。さらに、有意差は認められないものの、カプセルE(β−カロチン+エラスチン)摂取群及びカプセルF(β−カロチン+セラミド)摂取群のΔa値も低い傾向にあった。また図2に示すように、摂取開始後8週間の時点では、カプセルH(β−カロチン+エラスチン+セラミド)及びカプセルF(β−カロチン+セラミド)を摂取した2群が、カプセルA(コントロール)摂取群に比べてΔa値が有意に低かった。有意差は認められなかったものの、カプセルE(β−カロチン+エラスチン)摂取群とカプセルB(β−カロチン単独)摂取群のΔa値も、カプセルA(コントロール)摂取群に比べて低い傾向にあり、かつカプセルE(β−カロチン+エラスチン)摂取群の方がカプセルB(β−カロチン単独)摂取群よりもΔa値が低い傾向が認められた。以上の結果から、β−カロチンを単独で摂取するよりも、エラスチンとセラミドのいずれか一方又は両方をβ−カロチンと同時に摂取した方が、紫外線による皮膚の炎症を、より短期間かつ効果的に抑制できることが確認された。
【0022】
実施例2
β−カロチン含有植物油懸濁液をトマトオレオレジン(6%リコピン含有、ライコレッド社製)に変更し、実施例1と同様にAからHまでの8種類のカプセルを調製した。カプセル内容液の配合を表3に、カプセル1粒(内容液500mg)当たりの成分含有量を表4に示す。
【0023】
【表3】
Figure 2004229611
【0024】
【表4】
Figure 2004229611
【0025】
24人のボランティア(男性15人、女性9人、平均年齢29歳)を3人づつ8群に分け、前記の方法によって調製したAからHまでの8種類のカプセルを各群に割り当て、毎日2粒を1日2回に分けて8週間にわたり摂取させた。摂取開始前、摂取開始後4週間および8週間経過の時点で、紫外線照射による皮膚の炎症の程度を評価した。評価方法は実施例1と同じである。摂取開始後4週間の時点における紫外線照射による皮膚のΔaの測定値(各群での平均値)を図3に、摂取開始後8週間の時点における紫外線照射による皮膚のΔaの測定値(各群での平均値)を図4に示す。
【0026】
図3に示すように、摂取開始後4週間の時点では、カプセルH(リコピン+エラスチン+セラミド)摂取群が、カプセルA(コントロール)摂取群に比べてΔa値が有意に低く、紫外線照射による皮膚の発赤、すなわち炎症が有意に抑制されていた。さらに、有意差は認められないものの、カプセルE(リコピン+エラスチン)摂取群及びカプセルF(リコピン+セラミド)摂取群のΔa値も低い傾向にあった。また図4に示すように、摂取開始後8週間の時点では、カプセルH(リコピン+エラスチン+セラミド)、カプセルE(リコピン+エラスチン)及びカプセルF(リコピン+セラミド)を摂取した3群が、カプセルA(コントロール)摂取群に比べてΔa値が有意に低かった。カプセルB(リコピン単独)摂取群のΔa値も、カプセルA(コントロール)摂取群に比べて低い傾向にあったが、有意差は認められなかった。以上の結果から、リコピンを単独で摂取するよりも、エラスチンとセラミドのいずれか一方又は両方をリコピンと同時に摂取した方が、紫外線による皮膚の炎症を、より短期間かつ効果的に抑制できることが確認された。
【0027】
【発明の効果】
本発明によれば、β−カロチンやリコピンのようなカロチノイドに、エラスチンもしくはその分解物及び/又はセラミドもしくはその配糖体を加えてなる食品組成物は、紫外線により誘発される皮膚の炎症を予防又は軽減するのに有効である。
【図面の簡単な説明】
【図1】実施例1に記載の本発明の組成物及び比較組成物を4週間摂取した後の、紫外線照射による皮膚の色度(Δa)の変化を表したグラフである。
【図2】実施例1に記載の本発明の組成物及び比較組成物を8週間摂取した後の、紫外線照射による皮膚の色度(Δa)の変化を表したグラフである。
【図3】実施例2に記載の本発明の組成物及び比較組成物を4週間摂取した後の、紫外線照射による皮膚の色度(Δa)の変化を表したグラフである。
【図4】実施例2に記載の本発明の組成物及び比較組成物を8週間摂取した後の、紫外線照射による皮膚の色度(Δa)の変化を表したグラフである。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a food composition for preventing or reducing skin inflammation induced by ultraviolet rays and accompanying skin deterioration.
[0002]
[Prior art]
In recent years, with the expansion of the ozone hole, an increase in health damage caused by ultraviolet rays has become a global problem. According to a report by the Japan Meteorological Agency, the ozone hole above the Antarctic, which was rarely seen in 1979 when the observation was started, has continued to expand rapidly, reaching about 30 million square kilometers in 2000. (See Non-Patent Document 1). This is about twice the size of Antarctica. No clear ozone hole has been observed so far in the Northern Hemisphere, but as in the Southern Hemisphere, the amount of ozone in the sky has been decreasing, and as a result, an increase in the amount of harmful ultraviolet rays reaching the surface has been confirmed.
[0003]
In Australia near Antarctica, it is reported that the incidence of skin cancer due to ultraviolet rays is overwhelmingly higher than in other countries (see Non-Patent Document 2). In Finland in the Northern Hemisphere, it is also reported that the incidence of skin cancer is increasing year by year (see Non-Patent Document 3). In Japan, too, a long-term decrease in the amount of ozone in the sky has been observed, especially in high-latitude regions (see Non-Patent Document 1), and it is feared that diseases caused by ultraviolet rays, such as skin cancer, will increase in the future. .
[0004]
Exposure of the skin to intense UV radiation causes damage such as erythema (skin redness) and edema, resulting in skin deterioration such as thickening, loss of elasticity, wrinkling and abnormal pigmentation. In addition, repeated exposure to intense UV radiation increases the risk of skin cancer. On the other hand, it has been reported that weak ultraviolet rays to which the skin is exposed throughout the year, so-called living ultraviolet rays, also cause skin deterioration (see Non-Patent Document 4). In order to prevent such health damage caused by ultraviolet rays, external preparations such as sun creams and cosmetics applied to the skin have been used as main means for protecting the skin from ultraviolet rays. However, it is not only difficult to completely apply the skin external preparation to all exposed parts of the body every time you go out, but it takes time and effort, so it is easier and more effective to use ultraviolet light. Measures are needed.
[0005]
In order to solve this problem, many studies have been made on pharmacological components that have the effect of protecting the skin from ultraviolet rays by oral ingestion. It has been reported that the levels of vitamin C, vitamin E, and carotenoids in human skin are reduced by exposure to ultraviolet light. Based on these findings, it has been studied whether humans can reduce the damage of skin caused by ultraviolet rays when they ingest vitamin C, vitamin E, and carotenoids orally. Taking carotenoids as an example, it has been reported that oral ingestion of β-carotene and lycopene suppressed skin-induced inflammation (erythema) induced by ultraviolet rays (for example, see Non-Patent Documents 5 and 6). . However, ingestion of these carotenoids alone requires not only a long time of about 10 weeks until the effect is recognized, but also it is said that the effect of suppressing erythema is sufficient compared to skin external preparations such as cosmetics. There was a disadvantage that it was difficult.
[0006]
In addition, it has been reported that ultraviolet rays not only reduce the levels of vitamin C, vitamin E, and carotenoids in the skin, but also reduce the amount of elastic tissue in the skin (see Non-Patent Document 7). A major component of the elastic tissue of the skin is a protein called elastin present in the dermis, which contains a unique amino acid such as desmosine and isodesmosine, and is therefore attracting attention in nutritional terms. However, with regard to the effect on skin by oral ingestion of elastin, it has only been reported by animal studies that the recovery of burned skin is accelerated (see Non-Patent Document 8). No reports have been reported not only in studies but also in animal studies.
[0007]
On the other hand, the outermost epidermis of the skin is directly exposed to ultraviolet light, and ceramide, which accounts for about half of the intercellular lipids in the stratum corneum of the epidermis, is thought to have some protective effect against ultraviolet light. Is done. In fact, it has been reported that ceramide has an inhibitory effect on melanin production (see Non-Patent Document 9), but this is an in vitro result using melanoma cells, and humans and animals took ceramide orally. No effect was reported. As examples of oral ingestion, health foods and the like containing ceramide as an active ingredient have been proposed, but these are mainly intended for moisturizing and beautiful skin (see Patent Document 1 and Non-Patent Document 10). ).
[0008]
[Patent Document 1]
JP-A-11-113530 [Non-Patent Document 1]
JMA Climate Change Monitoring Report 2001
[Non-patent document 2]
Arch. Darmatol. , Vol. 135, no. 7, 843-844 (1999)
[Non-Patent Document 3]
Arch. Darmatol. , Vol. 135, no. 7, 781-786 (1999)
[Non-patent document 4]
J. Invest. Dermatol. , Vol. 105, no. 6, 739-743 (1995)
[Non-Patent Document 5]
Proc. Soc. Exp. Biol. Med. , Vol. 233, 170-174 (2000)
[Non-Patent Document 6]
J. Nutr. , Vol. 131, 1449-1451 (2002)
[Non-Patent Document 7]
J. Invest. Dermatol. , Vol. 105, 739-743 (1995)
[Non-Patent Document 8]
No. 9, 1-7 (2001)
[Non-Patent Document 9]
FOOD Style 21, Vol. 5, No. 8, 24-33 (2001)
[Non-Patent Document 10]
FRAGANCE JOURNAL, 1995-1, 81-89 (1995)
[0009]
[Problems to be solved by the invention]
As described above, at present, a food composition that effectively suppresses skin inflammation due to ultraviolet light by oral ingestion has not yet been put to practical use. In view of these circumstances, the present invention provides a food composition that is more effective than a carotenoid alone in preventing or reducing ultraviolet-induced skin inflammation and accompanying skin deterioration. Things.
[0010]
[Means for Solving the Problems]
The present inventors have conducted intensive studies to achieve this object, and as a result, by ingesting a food composition comprising elastin or a degradation product thereof and / or ceramide or a glycoside thereof added to a carotenoid, carotenoids were reduced. The present inventors have found that erythema of the skin induced by ultraviolet rays can be more effectively suppressed than when taken alone, and have completed the present invention.
[0011]
That is, the present invention relates to a food composition aimed at preventing or reducing skin inflammation induced by ultraviolet rays and accompanying skin deterioration.
[0012]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described. The carotenoid used in the present invention does not ask the origin at all.If β-carotene is used, it may be extracted from vegetables such as carrots and tomatoes or from algae such as Dunaliella, and if lycopene is used, it may be obtained from tomatoes. The extracted one is desirable. There is no problem even if other carotenoids, that is, α-carotene, lutein, zeaxanthin, β-cryptoxanthin, etc. are contained, and a mixed carotenoid obtained by mixing these can be used. These carotenoid extracts are generally viscous liquids extracted with fats and oils or solvents, and can be used as they are, or may be powdered with an excipient.
[0013]
There is no limitation on the origin of elastin used in the present invention, and elastin extracted from skin or connective tissue of mammals or fish is preferred. In addition, elastin as extracted or elastin hydrolyzate that has been chemically or enzymatically treated may be used, and a mixture thereof may also be used. One example of these is elastin, which is produced by shredding and homogenizing cod rind, extracting with hot water, partially hydrolyzing by enzymatic treatment, and pulverizing.
[0014]
Ceramide used in the present invention is defined as a general term for sphingosine in which a fatty acid is amide-bonded, and there are some differences in the constituent molecular species depending on the origin thereof, but this does not matter here. Animal ceramides extracted from tissues such as cattle and ceramides derived from microorganisms extracted from yeasts and the like may be used, but more preferably vegetable ceramides present as glycosides, that is, generally available It is desirable to use ceramide glycosides extracted from natural rice bran, wheat, konjac potatoes and the like. One example of these is ceramide, which is produced by pulverizing konjac potato, extracting it with alcohol, and then pulverizing it.
[0015]
The food composition of the present invention produced from these raw materials is characterized in that elastin or a decomposition product thereof and / or ceramide or a glycoside thereof are added to a carotenoid, and 1 part by weight of total carotenoid or β-carotene or lycopene is provided. On the other hand, elastin or its decomposed product is 0.1 to 100 parts by weight, ceramide or its glycoside is 0.001 to 1 part by weight, preferably, 1 part by weight of total carotenoid or β-carotene or lycopene. On the other hand, elastin or its degradation product is 1 to 10 parts by weight, and ceramide or its glycoside is 0.01 to 0.1 parts by weight. When the food composition of the present invention is ingested, a daily amount of carotenoid-equivalent 1 to 100 mg, preferably 20 to 50 mg as β-carotene, or 10 to 30 mg as lycopene is formulated as a daily food. By taking, it is possible to prevent or reduce inflammation of the skin due to ultraviolet rays and its accompanying deterioration more effectively in a shorter period of time than when carotenoids are taken alone.
[0016]
The food composition according to the present invention can be used alone or other nutrients which are considered to be good for maintaining skin health, such as vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, biotin, pantothenic acid, Combined with vitamins such as vitamin C and vitamin E, minerals such as zinc, selenium, and sulfur, as well as amino acids, glutathione, collagen or its degradation products, chondroitin, hyaluronic acid, squalene, isoflavone glycosides, or aglycones thereof. It can be used. Also, there is no limitation on the embodiment of such a food composition, and by appropriately combining with other food materials, in addition to solid preparations such as capsules and tablets, general solid, semi-solid, liquid, It can be used for powdered foods or beverages.
[0017]
【Example】
Examples are shown below, but the present invention is not limited by these.
Example 1
Based on olive oil with beeswax added as a thickener (control, solution A), and with only vegetable oil suspension containing β-carotene derived from Dunaliella (containing 30% β-carotene, manufactured by Kyowa Hakko Kogyo) (Solution B), a mixture containing only elastin (95% elastin, manufactured by Aswell) derived from cod skin (solution C), and only a ceramide derived from konjac (3% ceramide glycoside, manufactured by Unitika) A mixture (solution D), a mixture of vegetable oil suspension containing β-carotene and cod skin elastin (solution E), a mixture of vegetable oil suspension containing β-carotene and konjac ceramide (solution F), cod A mixture of skin elastin and konjac ceramide (solution G), β-carotene-containing vegetable oil suspension and cod skin elastin and konjac ceramide (Solution H) were prepared, and gelatin soft capsules (A to H) were prepared by using these solutions. Table 1 shows the composition of the capsule contents liquid, and Table 2 shows the component content per capsule (500 mg of contents liquid).
[0018]
[Table 1]
Figure 2004229611
[0019]
[Table 2]
Figure 2004229611
[0020]
Twenty-four volunteers (17 males, 7 females, average age 32 years) were divided into 8 groups of 3 volunteers, and 8 types of capsules A to H prepared by the above method were allocated to each group, and 2 capsules were administered daily. The grains were taken twice a day for 8 weeks. Before the start of ingestion, and at the lapse of 4 weeks and 8 weeks after the start of ingestion, the degree of skin inflammation due to ultraviolet irradiation was evaluated. As an evaluation method, an ultraviolet protection film having a hole 2 cm square is wound around the inner part of the upper arm, and the skin color (L0, a0, b0; L is lightness, a And b represent chromaticity) using a colorimeter (Minolta Color Reader CR-10). Then, the ultraviolet ray for sunburn (Philips CLEO 20W × 6) was irradiated to the opening of the film from a fixed distance for 30 minutes, the skin color (L, a, b) after irradiation was measured again, and the skin before irradiation was measured. The difference from the color (ΔL, Δa, Δb) was calculated. In the measurement three times every four weeks, the measurement was not performed on the same part of the skin by shifting the film opening. FIG. 1 shows the measured values of skin Δa due to ultraviolet irradiation at four weeks after the start of ingestion (average value in each group), and the measured values of skin Δa due to ultraviolet irradiation at eight weeks after the start of ingestion (each group). 2 is shown in FIG. The Δa value represents a change in chromaticity in the red-green direction, and the larger the Δa value, the more the skin turns red, that is, the more erythema (inflammation due to ultraviolet rays) occurs.
[0021]
As shown in FIG. 1, at 4 weeks after the start of ingestion, the Δa value of the capsule H (β-carotene + elastin + ceramide) intake group was significantly lower than that of the capsule A (control) intake group, Redness of the skin due to, ie, inflammation was significantly suppressed. Furthermore, although no significant difference was observed, the Δa values of the capsule E (β-carotene + elastin) intake group and the capsule F (β-carotene + ceramide) intake group also tended to be low. Also, as shown in FIG. 2, at 8 weeks after the start of the ingestion, two groups that took capsule H (β-carotene + elastin + ceramide) and capsule F (β-carotene + ceramide) became capsule A (control). The Δa value was significantly lower than in the intake group. Although no significant difference was observed, the Δa value of the capsule E (β-carotene + elastin) intake group and the capsule B (β-carotene alone) intake group also tended to be lower than that of the capsule A (control) intake group. In addition, there was a tendency that the Δa value of the capsule E (β-carotene + elastin) intake group was lower than that of the capsule B (β-carotene alone) intake group. From the above results, rather than taking β-carotene alone, taking one or both of elastin and ceramide simultaneously with β-carotene, skin inflammation due to ultraviolet rays, more effectively in a shorter time It was confirmed that it could be suppressed.
[0022]
Example 2
The β-carotene-containing vegetable oil suspension was changed to tomato oleoresin (containing 6% lycopene, manufactured by Lycored), and eight types of capsules A to H were prepared in the same manner as in Example 1. Table 3 shows the composition of the capsule contents liquid, and Table 4 shows the component contents per capsule (500 mg of contents liquid).
[0023]
[Table 3]
Figure 2004229611
[0024]
[Table 4]
Figure 2004229611
[0025]
Twenty-four volunteers (15 males, 9 females, average age 29 years old) were divided into 8 groups of 3 volunteers, and 8 types of capsules A to H prepared by the above-mentioned method were allocated to each group. The grains were taken twice a day for 8 weeks. Before the start of ingestion, and at the lapse of 4 weeks and 8 weeks after the start of ingestion, the degree of skin inflammation due to ultraviolet irradiation was evaluated. The evaluation method is the same as in the first embodiment. FIG. 3 shows the measured value of skin Δa due to ultraviolet irradiation at four weeks after the start of ingestion (average value in each group), and the measured value of skin Δa by ultraviolet irradiation at eight weeks after the start of ingestion (each group). 4 is shown in FIG.
[0026]
As shown in FIG. 3, at 4 weeks after the start of ingestion, the capsule H (lycopene + elastin + ceramide) intake group had a significantly lower Δa value than the capsule A (control) intake group, and the skin due to ultraviolet irradiation. Redness, ie, inflammation, was significantly suppressed. Further, although no significant difference was observed, the Δa values of the capsule E (lycopene + elastin) intake group and the capsule F (lycopene + ceramide) intake group also tended to be low. As shown in FIG. 4, at 8 weeks after the start of ingestion, three groups that took capsule H (lycopene + elastin + ceramide), capsule E (lycopene + elastin), and capsule F (lycopene + ceramide) had capsules The Δa value was significantly lower than in the A (control) intake group. The Δa value of the capsule B (lycopene only) intake group also tended to be lower than that of the capsule A (control) intake group, but no significant difference was observed. From the above results, it was confirmed that ingestion of one or both of elastin and ceramide simultaneously with lycopene can suppress skin inflammation due to ultraviolet rays more effectively and in a shorter period of time than ingestion of lycopene alone. Was done.
[0027]
【The invention's effect】
According to the present invention, a food composition comprising a carotenoid such as β-carotene or lycopene and elastin or a hydrolyzate thereof and / or ceramide or a glycoside thereof can prevent ultraviolet-induced skin inflammation. Or it is effective to reduce.
[Brief description of the drawings]
FIG. 1 is a graph showing changes in skin chromaticity (Δa) due to ultraviolet irradiation after ingestion of the composition of the present invention described in Example 1 and a comparative composition for 4 weeks.
FIG. 2 is a graph showing changes in skin chromaticity (Δa) due to ultraviolet irradiation after ingesting the composition of the present invention described in Example 1 and a comparative composition for 8 weeks.
FIG. 3 is a graph showing changes in skin chromaticity (Δa) due to ultraviolet irradiation after ingesting the composition of the present invention described in Example 2 and a comparative composition for 4 weeks.
FIG. 4 is a graph showing changes in skin chromaticity (Δa) due to ultraviolet irradiation after ingesting the composition of the present invention described in Example 2 and a comparative composition for 8 weeks.

Claims (3)

カロチノイドにエラスチンもしくはその分解物及び/又はセラミドもしくはその配糖体を加えてなる食品組成物。A food composition comprising a carotenoid and elastin or a decomposition product thereof and / or ceramide or a glycoside thereof. カロチノイドがβ−カロチン又はリコピンである、請求項1に記載の食品組成物。The food composition according to claim 1, wherein the carotenoid is β-carotene or lycopene. 紫外線により誘発される皮膚の炎症とそれに伴う皮膚の劣化を予防又は軽減することを目的とした、請求項1又は2に記載の食品組成物。3. The food composition according to claim 1, wherein the food composition is intended to prevent or reduce skin inflammation induced by ultraviolet rays and accompanying skin deterioration.
JP2003025049A 2003-01-31 2003-01-31 Anti-ultraviolet food composition Expired - Fee Related JP4114186B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003025049A JP4114186B2 (en) 2003-01-31 2003-01-31 Anti-ultraviolet food composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003025049A JP4114186B2 (en) 2003-01-31 2003-01-31 Anti-ultraviolet food composition

Publications (2)

Publication Number Publication Date
JP2004229611A true JP2004229611A (en) 2004-08-19
JP4114186B2 JP4114186B2 (en) 2008-07-09

Family

ID=32953421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003025049A Expired - Fee Related JP4114186B2 (en) 2003-01-31 2003-01-31 Anti-ultraviolet food composition

Country Status (1)

Country Link
JP (1) JP4114186B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046626A1 (en) * 2004-10-29 2006-05-04 Kyushu Institute Of Technology Water-soluble elastins, process for producing the same, and food and medicine containing the same
JP2017178842A (en) * 2016-03-30 2017-10-05 小林製薬株式会社 Dermal fibroblast activator and use therefor
JP2020130056A (en) * 2019-02-20 2020-08-31 株式会社ダイセル Oral composition for improving skin barrier function

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11113530A (en) * 1997-10-21 1999-04-27 Nof Corp Health food containing ceramide
JP2002003390A (en) * 2000-06-26 2002-01-09 Maruzen Pharmaceut Co Ltd Fibroblast growth agent, food and drink for beauty culture and skin cosmetic
JP2002003393A (en) * 2000-06-26 2002-01-09 Maruzen Pharmaceut Co Ltd Fibroblast growth agent, food and drink for beauty culture and skin cosmetic
JP2002029980A (en) * 2000-07-12 2002-01-29 Maruzen Pharmaceut Co Ltd Estrogenic agent and collagen production rpomoter, fibroblast proliferative agent, food for cosmetological use and skin cosmetic
JP2002068993A (en) * 2000-08-30 2002-03-08 Maruzen Pharmaceut Co Ltd Epidermal keratinizing cell propagation-accelerating agent, beautifying food and skin cosmetic
JP2002226323A (en) * 2001-02-02 2002-08-14 Maruzen Pharmaceut Co Ltd Collagen production promoter, collagenase inhibitor, fibroblast proliferation agent, elastase inhibitor, estrogen-like action agent, skin cosmetic, and beautifying drink or food
JP2002238496A (en) * 2001-02-19 2002-08-27 Araiansu:Kk Medical health food

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11113530A (en) * 1997-10-21 1999-04-27 Nof Corp Health food containing ceramide
JP2002003390A (en) * 2000-06-26 2002-01-09 Maruzen Pharmaceut Co Ltd Fibroblast growth agent, food and drink for beauty culture and skin cosmetic
JP2002003393A (en) * 2000-06-26 2002-01-09 Maruzen Pharmaceut Co Ltd Fibroblast growth agent, food and drink for beauty culture and skin cosmetic
JP2002029980A (en) * 2000-07-12 2002-01-29 Maruzen Pharmaceut Co Ltd Estrogenic agent and collagen production rpomoter, fibroblast proliferative agent, food for cosmetological use and skin cosmetic
JP2002068993A (en) * 2000-08-30 2002-03-08 Maruzen Pharmaceut Co Ltd Epidermal keratinizing cell propagation-accelerating agent, beautifying food and skin cosmetic
JP2002226323A (en) * 2001-02-02 2002-08-14 Maruzen Pharmaceut Co Ltd Collagen production promoter, collagenase inhibitor, fibroblast proliferation agent, elastase inhibitor, estrogen-like action agent, skin cosmetic, and beautifying drink or food
JP2002238496A (en) * 2001-02-19 2002-08-27 Araiansu:Kk Medical health food

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
エラスチンカプセル、<HTTP://COSME.BEAUTY.YAHOO.CO.JP/273179/> 2007-11-15投稿, [RETRIEVED ON 2007-12-, JPN6007013772, ISSN: 0000945722 *
ヘルスライフビジネス, vol. p.19, JPN6007013770, 1 June 2001 (2001-06-01), ISSN: 0000945720 *
健康産業新聞, JPN6007013771, 6 July 2003 (2003-07-06), pages 15 - 18, ISSN: 0000945721 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046626A1 (en) * 2004-10-29 2006-05-04 Kyushu Institute Of Technology Water-soluble elastins, process for producing the same, and food and medicine containing the same
US7851441B2 (en) 2004-10-29 2010-12-14 Kyushu Institute Of Technology Water-soluble elastin, process for producing same, and food and medicine containing same
JP2017178842A (en) * 2016-03-30 2017-10-05 小林製薬株式会社 Dermal fibroblast activator and use therefor
JP2020130056A (en) * 2019-02-20 2020-08-31 株式会社ダイセル Oral composition for improving skin barrier function

Also Published As

Publication number Publication date
JP4114186B2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
JP3966922B2 (en) Fibroblast growth promoter
ES2658865T3 (en) Composition that includes an unsaponifiable fraction
EP1667699B1 (en) Compositions comprising lotus extracts and methyl donors
JP4205188B2 (en) Maillard reaction inhibitor
JP2003095913A (en) Cosmetic composition or food and drink
JP4336486B2 (en) Hyaluronic acid production promoter
JP4100911B2 (en) Glutamate decarboxylase activator
JP5089888B2 (en) Fugu-derived collagen, derivatives thereof, production method thereof, and cosmetics containing the collagen and derivatives thereof
JP2002255803A (en) Phototoxicity inhibitor comprising extract from tussilago farfara l.
EP3090781A1 (en) Anti-age composition with plant extracts
JP2001321121A (en) Hair growing and restoring food and drink
US20060292094A1 (en) Composition and method of protection against UV irradiation
Spiro et al. Nutraceuticals and skin appearance: Is there any evidence to support this growing trend?
JP2002138044A (en) Inhibitor for inhibiting differentiation induction of pre- adipocyte
WO2010112071A1 (en) Combination of astaxanthin, antioxidants and colouring agents with sunscreen effect to be administered orally
JP2002104924A (en) Photo aging-preventing agent
JP2006124356A (en) INTERLEUKIN-1alpha PRODUCTION INHIBITOR
JP2006316069A (en) Cosmetic composition for pimples
JP2002363088A (en) Elastase activity inhibitor or cosmetic composition
JP4033808B2 (en) Beauty / health material containing Himefuuro extract
JP2001081037A (en) Cosmetic composition
JP2001122760A (en) Cosmetic composition containing moisturizing plant extract
CN106361667B (en) Snake oil ointment
JP2004238310A (en) Cosmetic composition, drink or food
JP4114186B2 (en) Anti-ultraviolet food composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080404

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140425

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees